PLK1 and cancer: Increasing evidence suggests that targeting upstream regulatory factors such as histone deacetylase (HDAC), phosphoinositol 3-kinase (PI3K), polo-like kinase 1 (PLK1) and BET bromodomain can lower MYC protein levels and inhibit MYC-driven cancer growth [18–21].